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Prognosticationa b s t r a c t
Whether the number of chemotherapy cycles required to obtain a ﬁrst morphological remission affects
prognosis of patients with acute myeloid leukemia (AML) remains controversial. To clarify how achievement
of early remission might inﬂuence outcome of allogeneic hematopoietic cell transplantation (HCT), we
studied 220 consecutive adults with AML in ﬁrst morphological remission who underwent transplantation
after myeloablative or nonmyeloablative conditioning to investigate how the number of standard- or high-
dose induction courses required to achieve remission impacted post-HCT outcome. Three-year estimates of
overall survival were 65% (95% conﬁdence interval [CI] 56% to 73%), 56% (95% CI, 43% to 67%), and 23% (95% CI,
6% to 46%) for patients requiring 1 course, 2 courses, or >2 courses of induction therapy; corresponding
relapse estimates were 24% (95% CI, 17% to 31%), 43% (95% CI, 31% to 55%), and 58% (95% CI, 30% to 78%),
respectively. After covariate adjustment (minimal residual disease status, conditioning, age, cytogenetic
disease risk, type of consolidation chemotherapy, pre-HCT karyotype, and pre-HCT peripheral blood count
recovery), the hazard ratios for 2 or >2 induction courses versus 1 induction were 1.16 (95% CI, .73 to 1.85,
P ¼ .53) and 2.63 (95% CI, 1.24 to 5.57, P ¼ .011) for overall mortality, and 2.10 (95% CI, 1.27 to 3.48, P ¼ .004)
and 3.32 (95% CI, 1.42 to 7.78, P ¼ .006), respectively, for relapse. These ﬁndings indicate that the number of
induction courses required to achieve morphological remission in AML adds prognostic information for post-
HCT outcome that is independent of other prognostic factors.
 2015 American Society for Blood and Marrow Transplantation.INTRODUCTION
For many patients with acute myeloid leukemia (AML) in
ﬁrst remission, allogeneic hematopoietic cell transplantation
(HCT) is an effective consolidation therapy. Still, even in theabsence of morphologically detectable disease at the time of
transplantation, relapse remains a major cause of treatment
failure [1,2], although it is widely appreciated that the risk of
disease recurrence varies considerablyamongpatients.Hence,
there has been interest in understanding pretransplantation
factors that could serve as predictors of adverse post-HCT
outcome to inform patients accurately about likely treatment
outcomes and to develop risk-stratiﬁed transplantation
regimens.
Recent attention has focused on the role of pre-
transplantation minimal residual disease (MRD) as indicator
of increased risk of relapse after allogeneic HCT for patients
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predictive factors have been recognized, including cytoge-
netic risk, white blood cell count at diagnosis, time of blast
clearance, and the number of induction courses required to
enter remission [7-13]. The prognostic impact of early
remission achievement (ie, after the ﬁrst cycle of chemo-
therapy), however, has not been fully clariﬁed. Speciﬁcally, in
a large study conducted by the United Kingdom Medical
Research Council in the nontransplantation setting, response
after course 1 was strongly predictive of outcome [14]. On
the other hand, an analysis of 6 trials conducted by the
Eastern Cooperative Oncology Group indicated that the
outcome after induction therapy was not worse for patients
if residual leukemia was present 10 to 14 days after the start
of the ﬁrst course of therapy if a second, similar cycle of
treatment was given and patients subsequently achieved a
remission [15]. Nonetheless, achievement of an early ﬁrst
remission is recommended in a recent Working Party
consensus statement of the European LeukemiaNet as one of
the factors for AML risk assessment in the decision-making
process regarding allogeneic HCT. With this, a better under-
standing of how early remission achievement might inﬂu-
ence outcome of transplantation is imperative. To address
this, we investigated to what degree, if any, the number of
cycles of induction therapy required to achieve morpholog-
ical remission was associated with post-transplantation
outcome after adjustment for other predictive factors,
including pre-HCT MRD, in 220 consecutive patients who
underwent allogeneic HCT for AML in ﬁrst morphological
remission at our institution.PATIENTS AND METHODS
Study Cohort
Adult AML patients 18 years of age were included in this retrospective
study if they received induction therapy with “7 þ 3” or high-dose cytar-
abine-based regimens, provided they met the criteria for morphological
remission (ie, <5% blasts by light microscopy without extramedullary
disease) at pre-transplant evaluation. We included patients with or without
complete peripheral blood count recovery and regardless of the presence of
ﬂow cytometric or cytogenetic MRD at the time of HCT if they underwent
myeloablative or nonmyeloablative allogeneic HCT and received peripheral
blood or bone marrow as stem cell source. Patients were eligible for our
analyses regardless of whether the treatment regimen was changed during
reinduction therapy. We included all patients meeting these criteria be-
tween late April 2006 until April 2012. Analyses of the role of pre-HCT MRD
on outcome have been published previously [16-18]. We used the 2008
World Health Organization criteria to deﬁne AML [19] and the reﬁned
United Kingdom Medical Research Council criteria to assign cytogenetic
risk [20]. Pretransplantation comorbidities were assessed retrospectively
using the HCT-speciﬁc comorbidity index (HCT-CI) [21,22]. Treatment
response criteria were used as proposed by the European LeukemiaNet
[23]. Information on typing at the HLA-A, -B, -C, -DR, and -DQ locus was
collected. Criteria for diagnosis and grading of acute and chronic graft-
versus-host disease (GVHD) have been reported previously [24,25]. Infor-
mation on post-transplantation outcomes was captured via the long-term
follow-up program through medical records from our outpatient clinic
and local clinics that provided primary care for patients. All patients were
treated on institutional review boardeapproved protocols or standard
treatment plans and gave consent to their data being used for research in
accordance with the Declaration of Helsinki. Follow-up was current as of
April 24, 2014.Multiparameter Flow Cytometry Detection of MRD
Ten-color multiparameter ﬂow cytometry was performed on bone
marrow aspirates obtained as routine baseline assessment before HCT as
described previously [16-18]. The routine sensitivity of this assay was esti-
mated at .1%, although a higher level of sensitivity was possible for a subset
of leukemias featuring more frankly aberrant immunophenotypes. When
identiﬁed, the abnormal population was quantiﬁed as a percentage of the
total CD45þ white cell events. Any level of residual disease was considered
MRDpos [16-18].Statistical Analysis
Categorical patient characteristics were compared between patients
requiring 1, 2, or >2 courses of induction therapy using Fisher exact tests,
and continuous characteristics were compared with Kruskal Wallis tests.
Unadjusted probabilities of overall survival (OS) and relapse-free survival
(RFS) were estimated using the Kaplan-Meier method, and probabilities of
nonrelapse mortality (NRM), relapse, and acute as well as chronic GVHD
were summarized using cumulative incidence estimates. NRM was deﬁned
as death without prior relapse and was considered a competing risk for
relapse, whereas relapse was a competing risk for NRM; death was
considered a competing risk for acute and chronic GVHD. All outcomes
were treated as time-to-event endpoints. Outcomes between patients
requiring 1, 2, or >2 courses of induction therapy were compared using Cox
regression. Multivariate models included the following additional factors:
presence of MRD by multiparameter ﬂow cytometry (yes versus no), type
of conditioning regimen (nonmyeloablative versus myeloablative), age at
the time of HCT, HCT-CI, cytogenetic risk group at time of AML diagnosis
(unfavorable versus favorable/intermediate), type of AML at diagnosis
(secondary versus de novo), type of consolidation chemotherapy (none
versus high-dose cytarabineecontaining versus nonehigh-dose cytar-
abineecontaining), karyotype at time of HCT (normalized versus not
normalized for patients presenting with abnormal karyotypes), and pe-
ripheral blood counts at the time of HCT (not recovered versus recovered).
Missing cytogenetic risk and karyotype were accounted for as separate
categories. No adjustments were made for multiple comparisons, and all 2-
sided P values from the regression models were derived from the Wald
test. Statistical analyses were performed using STATA (StataCorp LP, College
Station, TX).RESULTS
Patient Characteristics
Our retrospective analyses included 220 patients under-
going ﬁrst myeloablative (n ¼ 151) or nonmyeloablative
(n ¼ 69) HCT from HLA-matched related or unrelated donors
between April 2006 and April 2012 for AML in ﬁrst
morphological remission (ie, <5% bone marrow blasts).
Among these, 136 patients achieved a remission after 1
course of induction therapy, whereas 66 and 16 required 2 or
>2 courses, respectively. In 41 of the 66 patients requiring 2
courses of induction chemotherapy, the therapeutic regimen
was changed for reinduction, whereas the treatment
regimen was changed at least once in all but 1 patient
requiring > 2 courses of therapy to achieve morphological
remission. The characteristics of the study population, in-
duction and consolidation chemotherapies, donors, and
transplantations stratiﬁed by number of induction courses
are summarized in Table 1. Whereas generally relatively well
balanced across these patient strata, statistically signiﬁcant
differences were noted with regard to gender distribution
(P ¼ .01), postremission consolidative chemotherapy
(P < .001), remission duration before HCT (P ¼ .002), and
proportion of patients with fully recovered peripheral blood
counts at the time of HCT (P ¼ .009).Acute and Chronic GVHD
The 120-day cumulative incidence of grade 3 or 4 acute
GVHD differed slightly but not statistically signiﬁcantly be-
tween patient strata, with estimates of 9% (95% conﬁdence
interval [CI], 5% to 15%), 17% (95% CI, 9% to 27%), and 13% (95%
CI, 2% to 35%) for patients requiring 1 course, 2 courses, or > 2
courses of induction therapy to achieve remission, respec-
tively (P> .13). Likewise, the 180-day cumulative incidences of
chronic GVHD were not statistically signiﬁcantly different
between these patient cohorts: 49% (41% to 57%) for those
who required 1 course of induction therapy, 53% (95% CI, 40%
to 64%) for those requiring 2 courses and 50% (95% CI, 25% to
71%) for those requiring >2 courses, respectively (P > .07).
Table 1
Pretransplantation Demographic and Clinical Characteristics of Study Cohort, Stratiﬁed by Number of Induction Courses before Complete Remission
Achievement
Characteristic All (N ¼ 220) 1 Induction Course
(n ¼ 138)
2 Induction Courses
(n ¼ 66)
>2 Induction Courses
(n ¼ 16)
P Value
Age at HCT, median (range), yr 51.9 (18.2-75.0) 51.5 (18.2-75.0) 51.9 (20.2-73.7) 61.1 (18.2-67.3) .22
Male gender 57.3% 50.0% 66.7% 81.3% .01
WBC at diagnosis, median,  103/mL 5.0 (.2-280) 4.2 (.3-238) 5.7 (.2-280) 34.9 (.6-145) .31
Cytogenetics .40
Favorable 4.6% 6.5% 1.5% 0%
Intermediate 67.3% 67.4% 65.2% 75.0%
Adverse 25.0% 22.5% 31.8% 18.8%
Missing 3.2% 3.6% 1.5% 6.3%
Secondary AML 37.7% 42.0% 30.3% 31.3% .25
Consolidation therapy <.001
No 16.8% 10.9% 16.7% 68.8%
Yes (HiDAC-containing) 70.9% 74.6% 75.8% 18.8%
Yes (not HiDAC-containing) 12.3% 14.5% 7.6% 12.5%
CR duration before HCT, median (range), d 116 (16-788) 121 (22-788) 120 (26-465) 59 (16-231) .0014
Recovered peripheral blood counts before HCT* 84.1% 87.7% 83.3% 56.3% .009
Routine cytogenetics before HCT .23
Normalized karyotype 48.2% 50.7% 45.5% 37.5%
Abnormal karyotype 11.4% 8.0% 18.2% 12.5%
Missing/noninformative data 40.5% 41.3% 36.4% 50.0%
HCT-CI .73
0 15.0% 13.0% 19.7% 12.5%
1-2 31.8% 30.4% 34.9% 31.3%
3 52.7% 55.8% 45.5% 56.3%
Missing .5% .7% 0% 0%
MRDpos at HCT by MFC 19.6% 16.7% 22.7% 31.3% .24
Myeloablative conditioning 68.6% 67.4% 75.8% 50.0% .12
Unrelated donor 61.8% 63.0% 60.6% 56.3% .82
Donor age, median (range), yr 40.1 (18.1-76.6) 40.1 (18.1-71.5) 38.6 (18.6-76.6) 43.7 (20.2-71.8) .55
HLA matching .32
Matched/identical 81.4% 82.6% 80.3% 75.0%
1 locus mismatch 16.8% 16.7% 15.2% 25.0%
2 loci mismatch 1.8% .7% 4.6% –
Conditioning regimen
L-TBI  Flu or Clo 31.4% 32.6% 24.2% 50.0%
Bu/Cy  L-TBI 26.4% 24.6% 33.3% 12.5%
Bu/Flu 14.1% 15.9% 12.1% 6.3%
H-TBI/Cy or H-TBI/Tepa/Flu 7.3% 3.6% 10.6% 25.0%
Treo/Flu  L-TBI 18.6% 21.7% 15.2% 6.3%
Flu/Radiolabeled Ab/L-TBI  Cy 2.3% 1.4% 4.5% 0%
Source of stem cells .07
PBSC 81.4% 84.1% 72.7% 93.8
BM 18.6% 15.9% 27.3% 6.3
GVHD prophylaxis
Calcineurin inhibitor þ methotrexate 55.5% 54.3% 59.1% 50.0%
Calcineurin inhibitor þ MMF 32.3% 32.6% 27.3% 50.0%
Cy  Calcineurin Inhibitor 9.5% 9.4% 12.1% 0%
Other 2.7% 3.6% 1.5% 0%
HiDAC indicates high-dose cytarabine; CR, complete remission; MFC, multiparameter ﬂow cytometry; L-TBI, low-dose total body irradiation; Flu, ﬂudarabine;
Clo, clofarabine; Bu, busulfan; Cy, cyclophosphamide; H-TBI, high-dose total body irradiation; Tepa; thiotepa; Treo, treosulfan; Ab, antibody; PBSC, peripheral
blood stem cells; BM, bone marrow; MMF, mycophenolate mofetil.
* Absolute neutrophil count (ANC) 1000/mL and platelets 100,000/mL.
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Post-HCT Outcome
There were 95 deaths, 73 relapses, and 36 NRM events
contributing to the probability estimates for OS, RFS,
relapse, and NRM. The median follow-up after HCT among
survivors was 4.0 (range, 1.4 to 7.7) years, 4.0 (range, 1.4 to
7.1) years, and 3.7 (range, 1.4 to 6.3) years for patients
requiring 1, 2, or >2 courses of induction therapy, respec-
tively. The 3-year estimates of OS were 65% (95% CI, 56% to
73%), 56% (95% CI, 43% to 67%), and 23% (95% CI, 6% to 46%)
for patients requiring 1 course, 2 courses, or > 2 courses of
induction therapy to achieve remission, respectively
(Figure 1A). For RFS, the corresponding estimates were 60%
(95% CI, 51% to 68%), 44% (95% CI, 31% to 56%), and 17% (95%
CI, 3% to 39%) (Figure 1B). The 3-year estimate of relapseamong patients who required 1 course of induction
chemotherapy was 24% (95% CI, 17% to 31%), whereas for
those requiring 2 and > 2 courses of induction therapy, this
risk was projected to be 43% (95% CI, 31% to 55) and 58%
(95% CI, 30% to 78%), respectively (Figure 1C). Finally, the 3-
year estimates of NRM were 16% (95% CI, 11% to 23%), 13%
(95% CI, 6% to 23%), and 25% (95% CI, 8% to 47%) for patients
requiring 1, 2, or >2 courses of induction therapy, respec-
tively (Figure 1D).
Relationship between Number of Induction Courses and
Post-HCT Outcome
Univariate regression models for OS, RFS, relapse, and
NRM were ﬁt to assess the relevance of the number of
induction courses as prognostic factor and indicated an
Figure 1. Association between number of induction courses and post-HCT outcome for AML patients in CR1. Estimates of OS (A), RFS (B), cumulative incidence of
relapse (C), and cumulative incidence of NRM (D) after myeloablative allogeneic HCT for AML in complete morphologic remission, shown individually for patients
who required 1 course (n ¼ 138; black, solid line), 2 courses (n ¼ 66; grey, solid line), or >2 courses (n ¼ 16; grey, dashed line) of induction therapy to achieve ﬁrst
complete remission.
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HCT outcome. Speciﬁcally, as summarized in Supplemental
Table 1, patients who required 2 induction courses had a
shorter RFS (hazard ratio [HR], 1.51; [95% CI, 1.00 to 2.28],
P ¼ .05) and increased risk of relapse (HR, 1.97; 95% CI, 1.21 to
3.23; P¼ .007) relative to thosewho required only 1 induction
course, whereas OS and NRM were not statistically signiﬁ-
cantly different (OS:HR,1.20; 95%CI, .77 to 1.88; P¼ .42;NRM:
HR, .82; 95% CI, .37 to 1.82; P ¼ .624). Moreover, requiring >2
induction courses to achieve ﬁrst complete remission was
signiﬁcantly associatedwith shorter OS (HR, 3.18; 95% CI,1.69
to 5.96; P < .001) and RFS (HR, 3.36; 95% CI, 1.83 to 6.17;
P < .001), increased risk of relapse (HR, 3.73; 95% CI, 1.78 to
7.83; P < .001), and a trend toward increased NRM (HR, 2.83;
95% CI, .97 to 8.25; P ¼ .06) relative to those requiring only 1
course of induction therapy.
Number of Induction Courses as Independent Prognostic
Factor
Next, multivariate models were ﬁtted for OS, RFS, relapse,
and NRM to assess the potential role of the number of in-
duction courses to achieve ﬁrst remission (1 versus 2 versus
>2) as an independent prognostic factor. We considered the
following covariates: MRD status, HCT type, age at HCT, HCT-
CI, cytogenetic disease risk at diagnosis, type of AML, type of
consolidation chemotherapy before HCT, pre-HCT karyotype,
and pre-HCT peripheral blood count recovery as covariates.
Final models were built with inclusion of covariates that
yielded P values of <.10 in univariate analyses (see
Supplemental Table 1). After adjustment for these factors,
the HR for 2 or> 2 induction courses versus 1 inductionwere
1.16 (95% CI, .73 to 1.85; P¼ .53) and 2.63 (95% CI, 1.24 to 5.57;
P ¼ .011) for overall mortality, 1.66 (95% CI, 1.09 to 2.54;
P¼ .018) and 2.84 (95% CI,1.44 to 5.60; P¼ .003) for failure for
RFS, 2.10 (95% CI, 1.27 to 3.48; P¼ .004) and 3.32 (95% CI, 1.42
to 7.78; P ¼ .006) for relapse, and .86 (95% CI, .38 to 1.99;P ¼ .73) and 1.79 (95% CI, .59 to 5.45; P ¼ .31) for NRM,
respectively (Table 2).DISCUSSION
It has become increasingly clear that post-treatment
data bear important prognostic information that can
signiﬁcantly reﬁne risk stratiﬁcation in AML. For example,
rapid clearance of peripheral blood blasts, determined
either by manual differential blood counts or by ﬂow
cytometry, is predictive of remission achievement and
survival [26-31]. Moreover, the presence of submicroscopic
amounts of residual AML, measured at various time points
during and after therapy, identiﬁes a subset of patients at
particularly high risk of overt disease recurrence and poor
outcome [3-6]. This is also true for assessments before
allogeneic HCT, a situation where MRD is now well recog-
nized as a strong, independent predictor for adverse post-
HCT outcome [3-6].
Intrinsically, however, post-treatment information en-
tails an assessment of the dynamic response of AML cells to
antileukemia therapy, which may not be fully captured by
single time point analyses. This notion is illustrated by
recent data from the Children’s Oncology Group AAML03P1
trial, in which patients who cleared MRD early after initia-
tion of chemotherapy and remained MRDneg at the end of
therapy had signiﬁcantly better outcomes than those who
were similarly MRDneg at the end of therapy but had pre-
viously documented ﬂow cytometric evidence of residual
disease at some point during therapy [32]. Thus, as a
snapshot assessment of the sensitivity of the patient’s leu-
kemia cells late in the course of treatment, it is plausible
that the knowledge gained from this assessment could be
reﬁned by including additional data from earlier time points
during the course of therapy to provide more dynamic
response information.
Table 2
Multivariate Cox Regression Models
Overall Mortality Failure for RFS Relapse NRM
Induction therapy
1 Induction course (n ¼ 138) 1 (Reference) 1 (Reference) 1 (Reference) 1 (Reference)
2 Induction courses (n ¼ 66) 1.16 (.73-1.85), P ¼ .532 1.66 (1.09-2.54), P ¼ .018 2.10 (1.27-3.48), P ¼ .004 .86 (.38-1.99), P ¼ .731
>2 Induction courses (n ¼ 16) 2.63 (1.24-5.57), P ¼ .011 2.84 (1.44-5.60), P ¼ .003 3.32 (1.42-7.78), P ¼ .006 1.79 (.59-5.45), P ¼ .308
MRD status
Negative (n ¼ 177) 1 (Reference) 1 (Reference) 1 (Reference) 1 (Reference)
Positive (n ¼ 43) 2.97 (1.77-4.98), P < .001 4.06 (2.43-6.77), P < .001 4.86 (2.71-8.70), P < .001 2.21 (.88-5.58), P ¼ .092
HCT type
Myeloablative (n ¼ 151) 1 (Reference) 1 (Reference) 1 (Reference) 1 (Reference)
Nonmyeloablative (n ¼ 69) 1.59 (.97-2.61), P ¼ .068 1.68 (1.12-2.52), P ¼ .012 1.43 (.87-2.35), P ¼ .159 1.89 (.86-4.13), P ¼ .113
Age (per 10 yr) 1.01 (.82-1.23), P ¼ .960 Not included Not included 1.26 (.89-1.77), P ¼ .188
Cytogenetic risk group
Intermediate/favorable (n ¼ 158) 1 (Reference) 1 (Reference) 1 (Reference) Not included
Adverse (n ¼ 55) 2.19 (1.23-3.91), P ¼ .008 2.06 (1.20-3.54), P ¼ .009 1.49 (.87-2.56), P ¼ .150
Consolidation before HCT Not included
No (n ¼ 37) 1 (Reference) 1 (Reference) 1 (Reference)
Yes, with HiDAC (n ¼ 156) 1.22 (.66-2.26), P ¼ .530 1.35 (.75-2.43), P ¼ .313 1.26 (.65-2.46), P ¼ .490
Yes, without HiDAC (n ¼ 27) 1.06 (.49-2.30), P ¼ .879 1.26 (.61-2.59), P ¼ .526 0.94 (.39-2.29), P ¼ .889
Pre-HCT karyotype
Normalized (n ¼ 106) 1 (Reference) 1 (Reference) Not included 1 (Reference)
Not normalized (n ¼ 25) 1.35 (.69-2.64), P ¼ .387 1.07 (.57-2.02), P ¼ .830 2.01 (.66-6.11), P ¼ .218
Pre-HCT blood counts*
Recovered (n ¼ 185) 1 (Reference) 1 (Reference) Not included 1 (Reference)
Not recovered (n ¼ 35) 1.32 (.77-2.27), P ¼ .308 1.52 (.91-2.53), P ¼ .111 1.63 (.73-3.60), P ¼ .232
Number of events: deaths ¼ 95; relapses ¼ 73; deaths without prior relapse ¼ 36.
Included are covariates that yielded a P value of <.10 in univariate analyses.
* Recovered: ANC 1000/mL and platelets 100,000/mL; not recovered: ANC <1000/mL and/or platelets <100,000/mL.
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strating that the early response to induction therapy, as
estimated by the number of induction courses required to
achieve initial remission, is associated with post trans-
plantation outcome independently of the pre-HCT MRD
status. These results thus extend previous studies by Keating
et al. [9] showing that the time to remission maintains its
prognostic relevance even after accounting for MRD,
arguably one of the most important prognostic factors
recognized to date for AML patients undergoing allogeneic
HCT. Although the present ﬁndings may represent only a
crude measure of chemosensitivity, data on the number of
induction courses do provide additional prognostic infor-
mation on expected outcomes beyond what can be gleaned
from the MRD status, and, therefore, could be useful to
educate patients. The data may also provide a more accurate
and, perhaps, better guide to risk-stratiﬁed decision-making.
Indeed, our study indicates that the constellation of early
remission achievement and absence of MRD at the time of
transplantation can identify a subset of patients with excel-
lent long-term outcome. For example, in our cohort, patients
undergoing myeloablative HCT had an estimated 3-year OS
of 80% (95% CI, 69% to 87%) and RFS of 79% (95% CI, 67% to
86%) if they required only 1 course of induction therapy to
achieve remission and were MRDneg during the pre-HCT
assessment.
As 1 potential limitation of our study, the majority of
patients were referred to our institution for trans-
plantation after having received induction and consolida-
tion chemotherapy elsewhere. Thus, although patients
generally received an anthracycline and cytarabine, many
variations were used, and the decision and timing to
initiate a second induction therapy cycle was not stan-
dardized. Because many patients were referred from else-
where, information on molecular testing was not
universally available and could thus not be included in ouranalyses; for example, data on NPM1 and FLT3-ITD status
were only available for 51 and 55 patients, respectively. We
also did not have MRD information available from time
points other than the pretransplantation assessment, as
systematic MRD measurements are not generally obtained
outside of clinical trials, and such data are, thus, not typi-
cally available to the transplantation physician. In the
future, it is likely that sequential MRD assessments will
become an integral part of the routine care of AML patients
and may offer an optimized approach to the dynamic
response monitoring. At least until then, information on
the number of induction courses required to achieve initial
remission may offer some value in the risk stratiﬁcation of
AML patients presenting for allogeneic transplantation
while in remission.ACKNOWLEDGMENTS
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